SCHEMBL17858732

SCHEMBL17858732

Cc1cncc(-c2cc(O)no2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.42
S1PR1 P21453 4/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TP53 P04637 1/20 0.36
S1PR3 Q99500 2/20 0.35
HCAR2 Q8TDS4 1/20 0.35
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP1B1 Q16678 1/20 0.34
CYP11B1 P15538 3/20 0.33
CYP11B2 P19099 3/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
PIK3CG P48736 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19737072 0.78 LMNA (0.35) TP53CYP11B1CYP11B2
SCHEMBL21083201 0.78 S1PR1 (0.34) S1PR1S1PR3
SCHEMBL2959768 0.76 NPC1 (0.56) S1PR1NPC1RAB9AMEN1KMT2A
SCHEMBL17858736 0.75 RAB9A (0.45) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL8378894 0.71 CYP2A6 (0.48) CYP2A6RAB9AKMT2ATP53CYP1A2
SCHEMBL3423606 0.71 CYP2A6 (0.61) CYP2A6S1PR1HCAR2CYP1A1CYP1B1
SCHEMBL3421746 0.69 CYP2A6 (0.59) CYP2A6S1PR1HCAR2CYP1A1CYP1B1
SCHEMBL3426054 0.69 CYP2A6 (0.59) CYP2A6S1PR1HCAR2CYP1A1CYP1B1
SCHEMBL16785594 0.68 LMNA (0.60) CYP2A6MEN1KMT2ACYP1A1CYP1A2
SCHEMBL5157687 0.67 RAB9A (0.61) NPC1RAB9AMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-12-21 US disclosed
WO-2016100347-A2 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 CYP2A6 3614/4885S1PR1 4540/4885NPC1 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.